8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General174 citations

Yu G, Zhu Y, Song C, Chen L, Tang Z, Wu T

Bioeffects Seen

Authors not listed · 2023

Share:

This stroke medication study was incorrectly classified as EMF research and contains no electromagnetic field exposure data.

Plain English Summary

Summary written for general audiences

This study appears to be misclassified in the EMF Research Hub database. It's actually a clinical trial comparing two stroke medications (tenecteplase vs alteplase) in 1,430 Chinese patients, with no electromagnetic field exposure or EMF-related health effects studied.

Why This Matters

This study has been incorrectly categorized as EMF research when it's actually a pharmaceutical trial comparing stroke treatments. The research examined thrombolytic medications for acute ischemic stroke patients, finding tenecteplase was non-inferior to alteplase for patient outcomes. This highlights the importance of accurate database categorization in EMF health research. When studies are misclassified, it can dilute the quality of evidence available to researchers and the public seeking reliable information about electromagnetic field health effects. The EMF research community needs robust systems to ensure only relevant studies inform our understanding of wireless radiation, power line fields, and other electromagnetic exposures that genuinely impact human health.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2023). Yu G, Zhu Y, Song C, Chen L, Tang Z, Wu T.
Show BibTeX
@article{yu_g_zhu_y_song_c_chen_l_tang_z_wu_t_ce3919,
  author = {Unknown},
  title = {Yu G, Zhu Y, Song C, Chen L, Tang Z, Wu T},
  year = {2023},
  doi = {10.1016/s0140-6736(22)02600-9},
  
}
DOI: 10.1016/s0140-6736(22)02600-9PubMed: 36774935

Quick Questions About This Study

This appears to be a database categorization error. The study compared stroke medications tenecteplase and alteplase in 1,430 patients, with no electromagnetic field exposures or EMF-related measurements involved in the research design or outcomes.
No, these are both thrombolytic medications used to dissolve blood clots in stroke patients. Neither drug has any connection to electromagnetic fields, wireless radiation, or other EMF sources that would warrant inclusion in EMF health research.
The trial enrolled 1,430 acute ischemic stroke patients across 53 Chinese medical centers to compare the effectiveness and safety of two clot-dissolving drugs, finding tenecteplase was non-inferior to the standard alteplase treatment.
This particular study examined only pharmaceutical interventions without any electromagnetic field components. However, separate EMF research has investigated whether certain electromagnetic exposures might affect stroke recovery, though that's unrelated to this medication comparison trial.
Misclassified studies can dilute research quality and mislead those seeking EMF health information. Proper categorization is essential for maintaining the integrity of EMF research databases and ensuring accurate evidence synthesis for public health guidance.